Evaluation of additional peripheral panretinal LASER-treatment on recurrences of macular edema due to CRVO undergoing anti-VEGF treatment with ranibizumab

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2014-002790-11-DE

Enrollment

Registered

2015-03-02

Start date

2015-06-08

Completion date

Unknown

Last updated

2020-05-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

MedDRA version: 20.0 Level: LLT Classification code 10054467 Term: Macular edema System Organ Class: 100000004853 MedDRA version: 20.0 Level: LLT Classification code 10007972 Term: Central retinal vein occlusion System Organ Class: 100000004853

Interventions

Trade Name: Lucentis Pharmaceutical Form: Solution for injection

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 30 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 30

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Main Objective: ;Secondary Objective: ;Primary end point(s):	—

Countries

Germany

Contacts

Public ContactDr. Christoph Coch

Studienzentrale des Studienzentrums Bonn (SZB)

christoph.coch@ukb.uni-bonn.de+4922828714018

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026